Kintara Q1 net loss $4.6M; pauses REM-001 to save $3M, continues VAL-083 trial

TuHURA Biosciences, Inc./NV

Net loss of $4.6M ($0.07/share) for quarter ended Sep 30, 2022, vs $6.0M ($0.25) a year ago.
Cash and equivalents $7.1M at Sep 30, down from $11.8M at Jun 30; net $1.9M from Lincoln Park equity line.
Paused REM-001 CMBC program to conserve cash; expects to save ~$3.0M through 2023.
VAL-083 GBM AGILE registrational study ongoing; top-line data expected around end of 2023.
Entered $20M purchase agreement with Lincoln Park Capital; $1.9M received as of Nov 8.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

TuHURA Biosciences, Inc./NV reported the three months ended September 30, 2022 results: net income net loss of approximately $4.6 million, or $0.07 per share, EPS $0.07 per share.

Period: the three months ended September 30, 2022
Net income: net loss of approximately $4.6 million, or $0.07 per share
EPS: $0.07 per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, Kintara reported a net loss of approximately $4.6 million, or $0.07 per share, compared to a net loss of approximately $6.0 million, or $0.25 per share, for the three months ended September 30, 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-22-024000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.